After Jardiance Heart Failure Successes, BI And Lilly Focus On Kidney
Phase III Stopped Early
Executive Summary
Jardiance, the best-selling SGLT2 inhibitor, has AstraZeneca’s same-class rival Farxiga firmly in its sights in renal disease after showing such a level of efficacy that the 6,600-patient EMPA-KIDNEY study has been halted.
You may also be interested in...
Boehringer Buoyed By Progress Of Oncology Pipeline
Boehringer Ingelheim is enjoying the financial benefits that have come from the strong growth of Jardiance and has upped its R&D spend to advance promising cancer and fibrosis assets.
Profile: Boehringer’s Andersen On Volleyball And Leadership Learnings, Storytelling
Boehringer Ingelheim’s Head of Human Pharma Regions, Timmo Rousku Andersen shares with Scrip glimpses of his life and professional journey including distinct parallels between sports and leadership against the backdrop of the wider commercialization efforts for blockbuster therapy Jardiance.
Boehringer Will Go 'Wide, Broad, Fast, Strong' If Jardiance Hits CKD Bullseye
Data is the new gold and Timmo Rousku Andersen, Boehringer Ingelheim’s corporate senior vice-president, head of global regions, outlines in an interview the German group's efforts to shape go-to-market models driven by data and insights. He also touches on digital therapeutics and how the firm’s R&D engine is pursuing deeper insights into interconnected disorders.